Eris Lifesciences Limited Stock

Equities

ERIS

INE406M01024

Pharmaceuticals

Market Closed - NSE India S.E. 07:51:18 2024-04-23 am EDT 5-day change 1st Jan Change
883 INR +0.16% Intraday chart for Eris Lifesciences Limited +3.40% -2.97%
Sales 2024 * 19.71B 237M Sales 2025 * 26.49B 318M Capitalization 120B 1.44B
Net income 2024 * 4.1B 49.16M Net income 2025 * 4.38B 52.55M EV / Sales 2024 * 6.62 x
Net Debt 2024 * 10.44B 125M Net Debt 2025 * 11.22B 135M EV / Sales 2025 * 4.95 x
P/E ratio 2024 *
29.4 x
P/E ratio 2025 *
27.1 x
Employees 3,548
Yield 2024 *
0.77%
Yield 2025 *
0.78%
Free-Float 24.65%
More Fundamentals * Assessed data
Dynamic Chart
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion MT
Transcript : Eris Lifesciences Limited - Shareholder/Analyst Call
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million RE
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion. CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited. CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026 CI
Transcript : Eris Lifesciences Limited, Q3 2024 Earnings Call, Feb 13, 2024
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion. CI
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns RE
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics CI
Indian shares set to open higher tracking Asian peers RE
More news

Latest transcript on Eris Lifesciences Limited

1 day+0.16%
1 week+1.83%
Current month+4.70%
1 month+4.66%
3 months+0.34%
6 months+6.87%
Current year-2.97%
More quotes
1 week
855.00
Extreme 855
894.00
1 month
824.30
Extreme 824.3
894.00
Current year
809.15
Extreme 809.15
962.90
1 year
602.00
Extreme 602
971.90
3 years
551.30
Extreme 551.3
971.90
5 years
321.00
Extreme 321
971.90
10 years
321.00
Extreme 321
971.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 07-01-26
President - 10-04-30
Director of Finance/CFO 44 12-12-31
Members of the board TitleAgeSince
Director/Board Member 53 21-01-04
Director/Board Member 44 18-04-29
Chief Executive Officer 50 07-01-26
More insiders
Date Price Change Volume
24-04-23 883 +0.16% 67 503
24-04-22 881.6 +0.74% 41,772
24-04-19 875.1 +0.55% 149,470
24-04-18 870.3 +0.36% 120,833
24-04-16 867.2 +1.54% 122,443

Delayed Quote NSE India S.E., April 23, 2024 at 06:02 am EDT

More quotes
Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
881.6 INR
Average target price
1,081 INR
Spread / Average Target
+22.58%
Consensus

Quarterly revenue - Rate of surprise